DOCSLIB.ORG

(Cd79a, L26) in Rare Cases of Extranodal Cytotoxic Peripheral T- (NK/T-) Cell Lymphomas Karin Blakolmer, M.D., Michael Vesely, M.D., J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Cd79a, L26) in Rare Cases of Extranodal Cytotoxic Peripheral T- (NK/T-) Cell Lymphomas Karin Blakolmer, M.D., Michael Vesely, M.D., J Immunoreactivity of B-Cell Markers (CD79a, L26) in Rare Cases of Extranodal Cytotoxic Peripheral T- (NK/T-) Cell Lymphomas Karin Blakolmer, M.D., Michael Vesely, M.D., J. Alain Kummer, M.D., Wolfgang Jurecka, M.D., Christine Mannhalter, Ph.D., Andreas Chott, M.D. Departments of Clinical Pathology (KB, AC), Laboratory Medicine (CM), and General Dermatology (WJ), General Hospital Vienna, University of Vienna, Vienna, Austria and Departments of Pathology, Free University Hospital, Amsterdam, The Netherlands (JAK), and Hospital Lainz, Vienna, Austria (MV) KEY WORDS: CD79a, L26, NK/T-cell lymphoma, Pe- The monoclonal antibodies L26 (CD20) and CD79a ripheral T-cell lymphoma. are very useful reagents for the immunohistochem- Mod Pathol 2000;13(7):766–772 ical assessment of B-cell lineage in lymphoprolifera- tive disorders. Although very few CD20-positive pe- Immunohistochemistry on paraffin-embedded sec- ripheral T-cell lymphomas (PTL) have been tions is a valuable technique in both diagnostic and reported, comprehensive analyses of CD79a reactiv- investigative pathology as it optimally combines ity in extranodal PTL and NK/T-cell lymphomas immunoreactivity and tissue morphology. Espe- have not been performed previously. This study in- cially in hematopathology, immunohistochemistry vestigated CD79a (clone JCB117) and CD20 reactiv- has become an integral part of the diagnostic ity in 94 extranodal non–B-cell lymphomas workup. An increasing number of antibodies that -are reactive on routinely processed tissue has con ؍ enteropathy-type intestinal T-cell lymphoma [n) -and pri- tributed substantially to the understanding of he ,[11 ؍ nasal NK/T-cell lymphoma [n ,[52 -and in 17 cases of matopoietic malignancies in general and to malig ([31 ؍ mary cutaneous PTL [n nodal PTL, unspecified. In four cases (enteropathy- nant lymphomas in particular. The report on the -and nasal revised European-American classification of lym [3 ؍ type intestinal T-cell lymphoma [n the majority of tumor phoid neoplasms includes a record of the most ,([1 ؍ NK/T-cell lymphoma [n cells stained for CD79a (all CD20 negative) and one characteristic immunophenotype for each lym- cutaneous PTL, unspecified, was CD20 positive phoma entity, and the majority of antigens listed (CD79a negative). Extensive immunophenotyping can be detected on paraffin sections by commer- and polymerase chain reaction–based molecular cially available antibodies (1, 2). Some antibodies, analyses revealed that all five B-cell marker–positive such as those that recognize CD20 and CD79a, have extranodal lymphomas had a cytotoxic phenotype gained widespread acceptance because they are and did indeed represent monoclonal peripheral considered to be largely B-lineage restricted and T-cell proliferations. To minimize the risk of misin- therefore useful for differential diagnosis of B-cell terpretation of lymphoma cell lineage, especially in versus T-cell lymphoma (3–9). Although occasional cases of extranodal lymphoproliferative disease, we examples of CD20-positive T-cell lymphomas have suggest the use of both CD79a and CD20 in combi- been reported (5, 10, 11), to our knowledge no case nation with a panel of antibodies reactive to T cells, of CD79a-positive peripheral T-cell lymphoma such as ␤F1 and CD5, and to T cells and NK cells, (PTL) has been published. During an ongoing study such as CD3, CD2, CD56, and TIA-1. on intestinal T-cell lymphomas, one of these cases showed reactivity to CD79a in a significant propor- tion of tumor cells. Prompted by this observation, additional cases of extranodal PTLs and NK/T-cell Copyright © 2000 by The United States and Canadian Academy of lymphomas were evaluated for immunoreactivity Pathology, Inc. to CD79a. This report describes the histopathologic, VOL. 13, NO. 7, P. 766, 2000 Printed in the U.S.A. Date of acceptance: January 10, 2000. immunophenotypic, molecular, and clinical find- Address reprint requests to: Andreas Chott, M.D., General Hospital Vi- ings of five cases, four of which were reactive to enna, Department of Clinical Pathology, Wa¨hringer Gu¨rtel 18–20, A-1090 Vienna, Austria; e-mail: [email protected]; fax: 431 405 34 02. CD79a and one to CD20. 766 MATERIALS AND METHODS peroxidase-conjugated streptavidin (Super Sensitive HRP Label; Biogenex, San Ramon, CA). Staining was Tissue developed using 3-amino-9-ethylcarbazole as the To study the reactivity of CD79a and CD20 in chromogen (Sigma) in the presence of H2O2. For the PTLs and NK/T-cell lymphomas, a total of 111 cases remaining antibodies, biotinylated horse antimouse were retrieved from the files of the Department of IgG was used as the secondary antibody followed by Clinical Pathology, General Hospital Vienna. Ac- Vectastain Elite ABC reagent (Vector Laboratories, cording to the World Health Organization (WHO) Burlingame, CA) and 3,3Ј-diaminobenzidine as a classification of neoplastic diseases of the hemato- chromogen (Fluka, Buchs, Switzerland) in the pres- poietic and lymphoid tissues (12), they were com- ence of H2O2. Nonspecific reactivity was assessed by posed of 52 cases of enteropathy-type intestinal omission of the primary antibodies. Staining of tumor T-cell lymphomas, 11 cases of nasal NK/T-cell lym- cells was scored: ϩ, more than 50% positive; Ϯ,20to phomas, 31 cases of primary cutaneous PTLs (my- 50% positive; Ϫ, fewer than 20% positive; Iϩ, individ- cosis fungoides [n ϭ 14], PTL unspecified [n ϭ 7], ual tumor cells positive. The latter score was used for and CD30-positive lymphoproliferative disease TIA-1 and GB-4 only. [n ϭ 10]), and 17 cases of nodal PTLs, unspecified. Histologic examination was done on formalin-fixed (7.5%, pH 7.4), paraffin-embedded tissue. Sections EBER In Situ Hybridization were stained with hematoxylin and eosin, periodic Fluorescein-labeled oligonucleotides comple- acid-Schiff, and Giemsa for routine histopathologic mentary to Epstein-Barr virus small nuclear RNA evaluation. One patient (Case 3) has been included (EBER) 1/2 were used according to the instructions in a previously published series on intestinal T-cell of the manufacturer (PNA ISH detection kit, Dako) lymphomas (13). under RNAse-free conditions. Immunohistochemistry T- and B-cell Clonality Analyses by Polymerase Immunostaining was done using the polyclonal Chain Reaction antibodies anti-CD3 (Dako, Copenhagen, Den- For the detection of T-cell and B-cell clonality, mark; 1:400) and TdT (Dako; 1:20) and the mono- polymerase chain reaction (PCR) techniques were clonal antibodies CD79a (clone JCB117; Dako; used to amplify rearranged T-cell receptor (TCR) 1:25), L26 (Dako; 1:200), CD34 (Immunotech, Mar- ␥-chain and immunoglobulin heavy chain genes, seille, France; 1:100), ␤F1 (T-Cell Sciences, Woburn, respectively, as described (14). Genomic DNA was MA; 1:10), CD1a (Novocastra, Newcastle, UK; 1:20), extracted from formalin-fixed, paraffin-embedded CD2 (Novocastra; 1:20), CD4 (Novocastra; 1:20), tissue by proteinase K digestion without detergents CD5 (Novocastra; 1:20), CD7 (Novocastra; 1:40), or EDTA according to Frank et al. (15). PCR prod- CD8 (Dako; 1:30), TIA-1 (Coulter, Hialeah, FL; ucts were separated on precast 6% polyacrylamide 1:800), CD56 (Sanbio, Uden, The Netherlands; gels (Novex, San Diego, CA). 1:200), CD57 (Becton-Dickinson, San Jose, CA; 1:10), CD30 (Dako; 1:80), EMA (Dako; 1:100), LMP1 (Dako; 1:100) and MIB-1 (Immunotech; 1:50). The RESULTS monoclonal antibody Granzyme B-4 (GB-4, 1:50) was generously provided by Dr. J.A. Kummer, De- Identification of Five Extranodal Peripheral partment of Pathology, Free University Hospital, T-(NK/T-) Cell Lymphomas Reactive to CD79a Amsterdam, The Netherlands. Pretreatment for un- or CD20 masking of antigens was done either by digestion A total of 111 cases of various types of extranodal with 0.05% preheated protease (type XXIV; Sigma PTL and NK/T-cell lymphomas and a group of Chemical Co., St.Louis, MO) in TRIS-buffered saline nodal PTL, unspecified, were studied for the immu- for 5 min at 37° C (for ␤F1 and CD3), by microwav- noreactivity of the B-cell markers CD79a and CD20 ing in citrate buffer (10 mmol/L, pH 6.0) twice for 5 on paraffin sections (Table 1). None of the 17 nodal min each at 600 W (for CD79a, CD34, TdT, CD1a, PTL was reactive to CD79a or CD20. In contrast, 5 of CD7, GB-4, TIA-1, CD30, EMA, LMP1, and MIB-1), or the 94 extranodal lymphomas (5.3%) stained either by autoclaving at 1 bar for 20 min, followed by cooling for CD79a (enteropathy-type intestinal T-cell lym- down for 40 min (for CD2, CD4, CD5, CD8, and phoma [n ϭ 3] and nasal NK/T-cell lymphoma [n ϭ CD56). Application of CD34, TdT, ␤F1, CD3, CD4, 1]) or for CD20 (primary cutaneous PTL, unspeci- CD5, and CD8 was followed by incubation with bio- fied [n ϭ 1]), indicating a mutually exclusive reac- tinylated goat antirabbit IgG (for TdT and CD3) or tivity pattern of the two B-cell markers. The clinical horse antimouse IgG (for CD34, ␤F1, CD4, CD5, and presentation and follow-up, histopathology, immu- CD8) as the secondary antibody and then by nologic phenotyping, and PCR-based clonality B-Cell Markers in Peripheral T-Cell Lymphomas (K. Blakolmer et al.) 767 TABLE 1. Peripheral T-Cell Lymphomas and NK/T-Cell of monomorphic small- to medium-sized cells that Lymphomas Evaluated for CD79a and CD20 Immunoreactivity were of monocytoid clear cell appearance (in Case 2) or displayed lymphoplasmacytoid features with Diagnosisa n CD79aϩ CD20ϩ narrow, slightly basophilic cytoplasm (in Giemsa- Enteropathy-type intestinal T-cell lymphoma 52 3 — Nasal NK/T-cell lymphoma 11 1 — stained sections) and inconspicuous nuclei (in Case Primary cutaneous PTL 3). As both of these cases additionally showed Mycosis fungoides 14 — — prominent intraepithelial lymphoma cell accumu- PTL, unspecified 7 — 1 CD30ϩ lymphoproliferative diseaseb 10 — — lations resembling lymphoepithelial lesions, they Nodal PTL, unspecified 17 — — strikingly mimicked low-grade B-cell lymphoma of Total 111 4 1 mucosa-associated lymphoid tissue (MALT) type.
Load more

Recommended publications
  • Costimulation of T-Cell Activation and Virus Production by B7 Antigen on Activated CD4+ T Cells from Human Immunodeficiency Virus Type 1-Infected Donors OMAR K
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11094-11098, December 1993 Immunology Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors OMAR K. HAFFAR, MOLLY D. SMITHGALL, JEFFREY BRADSHAW, BILL BRADY, NITIN K. DAMLE*, AND PETER S. LINSLEY Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121 Communicated by Leon E. Rosenberg, August 3, 1993 (receivedfor review April 29, 1993) ABSTRACT Infection with the human immunodeficiency sequence (CTLA-4) (34), a protein structurally related to virus type 1 (HIV-1) requires T-cefl activation. Recent studies CD28 but only expressed on T cells after activation (12). have shown that interactions of the T-lymphocyte receptors CTLA-4 acts cooperatively with CD28 to bind B7 and deliver CD28 and CTLA-4 with their counter receptor, B7, on antigen- T-cell costimulatory signals (13). presenting cells are required for optimal T-cell activation. Here Because of the importance of the CD28/CTLA-4 and B7 we show that HIV-1 infection is associated with decreased interactions in immune responses, it is likely that these expression of CD28 and increased expression of B7 on CD4+ interactions are also important during HIV-1 infection. Stud- T-cell lines generated from seropositive donors by afloantigen ies with anti-CD28 monoclonal antibodies (mAbs) suggested stimulation. Loss of CD28 expression was not seen on CD4+ a role for CD28 in up-regulating HIV-1 long terminal repeat- T-ceU lines from seronegative donors, but up-regulation of B7 driven transcription of a reporter gene in leukemic cell lines expression was observed upon more prolonged culture.
    [Show full text]
  • PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than Cd79a and Selective Association with T(8;21)-Acute Myelogenous Leukemia
    [CANCER RESEARCH 64, 7399–7404, October 15, 2004] PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than CD79a and Selective Association with t(8;21)-Acute Myelogenous Leukemia Enrico Tiacci,1 Stefano Pileri,2 Annette Orleth,1 Roberta Pacini,1 Alessia Tabarrini,1 Federica Frenguelli,1 Arcangelo Liso,3 Daniela Diverio,4 Francesco Lo-Coco,5 and Brunangelo Falini1 1Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy; 2Unit of Hematopathology, University of Bologne, Bologne, Italy; 3Section of Hematology, University of Foggia, Foggia, Italy; 4Department of Cellular Biotechnologies and Hematology, University La Sapienza of Rome, Rome, Italy; and 5Department of Biopathology, University Tor Vergata of Rome, Rome, Italy ABSTRACT (13, 16). PAX5 expression also occurs in the adult testis and in the mesencephalon and spinal cord during embryogenesis (17), suggesting an The transcription factor PAX5 plays a key role in the commitment of important role in the development of these tissues. hematopoietic precursors to the B-cell lineage, but its expression in acute Rearrangement of the PAX5 gene through reciprocal chromosomal leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and mye- translocations has been described in different types of B-cell malig- loid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts nancies (18–23), and, more recently, PAX5 has also been shown to be from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling targeted by aberrant hypermutation in Ͼ50% of diffuse large B-cell that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 lymphomas (24).
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Bispecific CAR-T Cells Targeting Both CD19 and CD22 for Therapy Of
    Dai et al. Journal of Hematology & Oncology (2020) 13:30 https://doi.org/10.1186/s13045-020-00856-8 RAPID COMMUNICATION Open Access Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia Hanren Dai1,2,3†, Zhiqiang Wu1†, Hejin Jia2†, Chuan Tong1, Yelei Guo1, Dongdong Ti1, Xiao Han1, Yang Liu4, Wenying Zhang2, Chunmeng Wang2, Yajing Zhang2, Meixia Chen2, Qingming Yang2, Yao Wang1* and Weidong Han1,2* Abstract Background: Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. Methods: We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight. Results: We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment.
    [Show full text]
  • CD74 Targeted Nanoparticles As Dexamethasone Delivery System for B Lymphoid Malignancies
    CD74 targeted nanoparticles as Dexamethasone Delivery System for B lymphoid malignancies DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Georgia Triantafillou, MPH Integrated Biomedical Sciences Graduate Program The Ohio State University 2011 Dissertation Committee John C. Byrd, MD, advisor Natarajan Muthusamy, PhD co-advisor Robert J.Lee, PhD, co-advisor Mitch A.Phelps, PhD, co-advisor Guido Marcucci, MD committee member Susheela Tridandapani, PhD committee member Copyright page Georgia Triantafillou 2011 ABSTRACT Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is not curable with standard therapy. In CLL the B lymphocytes appear morphologically mature but immunologically express less mature B cell makers. Specifically, the CLL B cells co-express surface antigens including CD19, CD20, CD5, CD23. Due to nonspecific delivery of the drugs to malignant as well as normal cells, patients experience numerous side effects. Targeted drug delivery to cancer cells is a desirable goal for all anti cancer strategies. Corticosteroids have been proven to be a beneficial and well established part of CLL treatment. Dexamethasone(DEX) is frequently used in CLL therapies as well as other malignancies and antiinflammatory diseases. However, DEX nonspecifically enters all tissues inducing various toxicities to patients. Therefore, DEX treatment is often discontinued or not administered to certain patients. We aimed to deliver this efficient clinical agent via a targeted delivery vehicle and examine its effect on its target B-CLL cells. The main scope of the work presented is the creation of a sterically stable nanoparticle, an ii immunoliposome (ILP), that has DEX encapsulated in its interior and a monoclonal antibody(Mab) in its exterior targeting CLL B cells expressing the surface antigen that is recognized by the Mab.
    [Show full text]
  • Molecules with Specificity for Cd45 and Cd79 Moleküle Mit Cd45- Und Cd79-Spezifizität Molécules Présentant Une Spécificité Vis-À-Vis De Cd45 Et Cd79
    (19) *EP003169704B1* (11) EP 3 169 704 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) 29.07.2020 Bulletin 2020/31 (86) International application number: (21) Application number: 15738655.8 PCT/EP2015/066368 (22) Date of filing: 16.07.2015 (87) International publication number: WO 2016/009029 (21.01.2016 Gazette 2016/03) (54) MOLECULES WITH SPECIFICITY FOR CD45 AND CD79 MOLEKÜLE MIT CD45- UND CD79-SPEZIFIZITÄT MOLÉCULES PRÉSENTANT UNE SPÉCIFICITÉ VIS-À-VIS DE CD45 ET CD79 (84) Designated Contracting States: • WRIGHT, Michael John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Slough GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Berkshire SL1 3WE (GB) PL PT RO RS SE SI SK SM TR • TYSON, Kerry Designated Extension States: Slough BA ME Berkshire SL1 3WE (GB) Designated Validation States: MA (74) Representative: UCB Intellectual Property c/o UCB Celltech (30) Priority: 16.07.2014 GB 201412659 IP Department 208 Bath Road (43) Date of publication of application: Slough, Berkshire SL1 3WE (GB) 24.05.2017 Bulletin 2017/21 (56) References cited: (73) Proprietor: UCB Biopharma SRL WO-A1-2011/025904 WO-A1-2013/085893 1070 Brussels (BE) • GOLD ET AL.: "The B Cell Antigen Receptor (72) Inventors: Activates the AKT/Glycogegn Synthase Kinase-3 • FINNEY, Helene Margaret Signalling Pathway via Phosphatydilinositol Slough 3-Kinase", J. IMMUNOLOGY, vol. 163, 1999, Berkshire SL1 3WE (GB) pages 1894-1905, XP002745175, • RAPECKI, Stephen Edward Slough Berkshire SL1 3WE (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • T Cells the Usual Subsets
    T cells: the usual subsets Chen Dong and Gustavo J. Martinez T cells have important roles in immune responses and function by directly secreting soluble mediators or important for adaptation of immune responses in different microenvironments and might be particularly through cell contact-dependent mechanisms. Many T cell subsets have been characterized. Although relevant for host defence against pathogens that colonize different tissues. Distinct T cell subsets, or effector T cells were originally considered to be terminally differentiated, a growing body of evidence has differentiation states, can be identified based on the cell surface markers expressed and/or the effector challenged this view and suggested that the phenotype of effector T cells is not completely fixed but is molecules produced by a particular T cell population. This Poster summarizes our current understanding of more flexible or plastic. T cells can have ‘mixed’ phenotypes (that is, have characteristics usually the surface markers, transcriptional regulators, effector molecules and functions of the different T cell associated with more than one T cell subset) and can interconvert from one subset phenotype to another, subsets that participate in immune responses. Further knowledge of how these T cell subsets are regulated IMMUNOLOGY although instructive signalling can lead to long-term fixation of cytokine memory. T cell plasticity can be and cooperate with each other will provide us with better tools to treat immune-related diseases. Cytotoxic T cell Exhausted T cell
    [Show full text]
  • ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays
    Leukemia (2006) 20, 2102–2110 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens AC Rawstron, R de Tute, AS Jack and P Hillmen Haematological Malignancy Diagnostic Service (HMDS), Leeds Teaching Hospitals, Leeds, UK Depletion of disease below the levels detected by sensitive sustained remissions only occur in patients achieving an MRD- minimal residual disease (MRD) assays is associated with negative complete response.12 Therefore MRD is increasingly prolonged survival in chronic lymphocytic leukaemia (CLL). being used as an end point for therapeutic trials, and several Flow cytometric MRD assays are now sufficiently sensitive and rapid to guide the duration of therapy in CLL, but generally rely studies are now using the assessment of MRD to define the on assessment of CD20 expression, which cannot be accurately duration of therapy. measured during and after therapeutic approaches containing Approaches using allele-specific oligonucleotide polymerase rituximab. The aim of this study was to use analytical software chain reaction (ASO-PCR) to the immunoglobulin gene of the developed for microarray analysis to provide a systematic B-CLL cell are generally accepted to show the highest sensitivity approach for MRD flow assay development. Samples from CLL for MRD detection. However, more recent four-colour ap- patients (n ¼ 49), normal controls (n ¼ 21) and other B-lympho- proaches show sensitivities nearing that of ASO-PCR6,11,13 with proliferative disorders (n ¼ 12) were assessed with a panel of 66 antibodies.
    [Show full text]
  • Single-Cell RNA Sequencing Identifies Candidate Renal
    BASIC RESEARCH www.jasn.org Single-Cell RNA Sequencing Identifies Candidate Renal Resident Macrophage Gene Expression Signatures across Species Kurt A. Zimmerman,1 Melissa R. Bentley,1 Jeremie M. Lever ,2 Zhang Li,1 David K. Crossman,3 Cheng Jack Song,1 Shanrun Liu,4 Michael R. Crowley,3 James F. George,5 Michal Mrug,2,6 and Bradley K. Yoder1 1Department of Cell, Developmental, and Integrative Biology, 2Division of Nephrology, Department of Medicine, 3Department of Genetics, 4Department of Biochemistry and Molecular Genetics, and 5Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama; and 6Department of Veterans Affairs Medical Center, Birmingham, Alabama ABSTRACT Background Resident macrophages regulate homeostatic and disease processes in multiple tissues, in- cluding the kidney. Despite having well defined markers to identify these cells in mice, technical limita- tions have prevented identification of a similar cell type across species. The inability to identify resident macrophage populations across species hinders the translation of data obtained from animal model to human patients. Methods As an entry point to determine novel markers that could identify resident macrophages across species, we performed single-cell RNA sequencing (scRNAseq) analysis of all T and B cell–negative CD45+ innate immune cells in mouse, rat, pig, and human kidney tissue. Results We identified genes with enriched expression in mouse renal resident macrophages that were also present in candidate resident macrophage populations across species. Using the scRNAseq data, we defined a novel set of possible cell surface markers (Cd74 and Cd81) for these candidate kidney resident macrophages. We confirmed, using parabiosis and flow cytometry, that these proteins are indeed enriched in mouse resident macrophages.
    [Show full text]
  • Papers J Clin Pathol: First Published As 10.1136/Jcp.49.7.539 on 1 July 1996
    Clin Pathol 1996;49:539-544 539 Papers J Clin Pathol: first published as 10.1136/jcp.49.7.539 on 1 July 1996. Downloaded from Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry L Ginaldi, N Farahat, E Matutes, M De Martinis, R Morilla, D Catovsky Abstract diagnosis by comparison with findings in Aims-To obtain reference values of the normal counterparts. level of expression of T cell antigens on ( Clin Pathol 1996;49:539-544) normal lymphocyte subsets in order to disclose differences which could reflect Keywords: flow cytometry, T cell antigens, peripheral their function or maturation stages, or blood lymphocytes. both. Methods-Peripheral blood from 15 healthy donors was processed by flow The most common use of flow cytometry is to cytometry with triple colour analysis. For determine the percent of "positive" or "nega- each sample phycoerythrin (PE) conju- tive" cells for each antigen in different cell gated CD2, CD4, CD5, CD8, and CD56 populations. However, valuable information is monoclonal antibodies were combined lost when the relative intensities of the positive with Cy5-R-phycoerythrin (TC) conju- cells, reflecting antigenic densities, are not considered. A cell population with a well gated CD3 and fluorescein isothiocyanate http://jcp.bmj.com/ (FITC) conjugated CD7; CD2- and defined phenotype, positive for one antigen, CD7-PE were also combined with might be heterogeneous with regard to its level CD3-TC and CD4-FITC. Standard mi- of expression. This may reflect different crobeads with different capacities to bind functional or maturational states, or both, or mouse immunoglobulins were used to identify subpopulations on the basis of the dif- convert the mean fluorescence intensity ferent numbers of molecules of antigen per cell.
    [Show full text]
  • T Lymphocytes + and CD8 +CD4 TCR/CD3 Complex in Immortalized Mature -Deficient Γ Signaling Through A
    Signaling Through a CD3γ-Deficient TCR/CD3 Complex in Immortalized Mature CD4+ and CD8+ T Lymphocytes This information is current as Alberto Pacheco-Castro, David Alvarez-Zapata, Pilar of September 25, 2021. Serrano-Torres and José R. Regueiro J Immunol 1998; 161:3152-3160; ; http://www.jimmunol.org/content/161/6/3152 Downloaded from References This article cites 47 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/161/6/3152.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Signaling Through a CD3g-Deficient TCR/CD3 Complex in Immortalized Mature CD41 and CD81 T Lymphocytes1 Alberto Pacheco-Castro,2 David Alvarez-Zapata,2 Pilar Serrano-Torres, and Jose´R. Regueiro3 The biologic role of each CD3 chain and their relative contribution to the signals transduced through the TCR/CD3 complex and to downstream activation events are still controversial: they may be specialized or redundant.
    [Show full text]
  • Cd1a [O10] Concentrated and Prediluted Monoclonal Antibody 901-3158-061719
    CD1a [O10] Concentrated and Prediluted Monoclonal Antibody 901-3158-061719 Catalog Number: ACI 3158 A, B API 3158 AA VLTM 3158 G20 Description: 0.1, 0.5 mL conc. 6.0 mL, RTU 20 mL, RTU Dilution: 1:100 Ready-to-use Ready-to-use Diluent: Van Gogh Yellow N/A N/A Intended Use: Protocol Recommendations (VALENT® Automated Slide For In Vitro Diagnostic Use Staining Platform) Cont’d: CD1a [O10] is a mouse monoclonal antibody that is intended for Protein Block (Optional): Incubate for 10-20 minutes at RT with Val laboratory use in the qualitative identification of CD1a protein by Background Block. immunohistochemistry (IHC) in formalin-fixed paraffin-embedded Primary Antibody: Incubate for 30 minutes. (FFPE) human tissues. The clinical interpretation of any staining or its Secondary: Incubate for 10 minutes with Val Mouse Secondary. absence should be complemented by morphological studies using proper Linker: Incubate for 10 minutes with Val Universal Linker. controls and should be evaluated within the context of the patient’s Polymer: Incubate for 10 minutes with Val Universal Polymer. clinical history and other diagnostic tests by a qualified pathologist. Chromogen: Incubate for 5 minutes with Val DAB. Summary and Explanation: Counterstain: Counterstain for 5 minutes with Val Hematoxylin. CD1a is a protein of 43 to 49 kDa and is expressed on dendritic cells and cortical thymocytes (1,2). CD1a [O10] staining has been shown to be Protocol Recommendations (intelliPATH FLX® and manual use): useful in the differentiation of Langerhans cells from interdigitating cells. Peroxide Block: Block for 5 minutes with Peroxidazed 1. It has also proved useful for phenotyping Langerhans cell histiocytosis Pretreatment: Perform heat retrieval using Diva or Reveal Decloaker.
    [Show full text]